Skip to main content

Table 6 Adverse events in 72 patients on Alirocumab 75 or 150 mg, or Evolocumab 140 mg, by treatment regimens

From: Efficacy, safety, Low density lipoprotein cholesterol lowering, and calculated 10-year cardiovascular risk reduction of alirocumab and evolocumab in addition to maximal tolerated cholesterol lowering therapy: a post-commercialization study

  All 3 treatment groups (n = 72) F45, M27 Follow up length median 25 weeks Alirocumab 75 mg (n = 25) F12, M13 Follow up length median 24 weeks Alirocumab 150 mg (n = 15) F10, M5 Follow up length median 26 weeks Evolocumab 140 mg (n = 32) F23, M9 Follow up length median 24 weeks
Flu-like myositis 8 (10%) 1 (4%) 5 (33%) 2 (6%)
Respiratory tract infection/symptoms 6 (8%) 1 (4%) 1 (7%) 4 (13%)
Inject site reaction 4 (6%) 1 (4%) 1 (7%) 2 (6%)
Fatigue 1 (1%) 1 (4%)   
Headache/mental acuity/mood 2 (3%)   1 (7%) 1 (3%)
Urticaria/itchiness 2 (3%) 1 (4%)   1 (3%)
G.I. symptom 2 (3%)   1 (7%) 1 (3%)
Weight gain 1 (1%)    1 (3%)
Hair loss 1 (1%)    1 (3%)
Any adverse events 22 (31%) 5 (20%) 7 (47%) 10 (31%)
No adverse events 50 (69%) 20 (80%) 8 (53%) 22 (69%)
  1. Comparing adverse events (any vs none), no difference among 3 treatment groups (Fisher’s p > .05)